Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening

Journal of Crohn's and Colitis

Volumn 8, Issue 6, 2014, Pages 550-557

  Debeuckelaere, Celine ^a   De Munter, Paul ^a   Van Bleyenbergh, Pascal ^a   De Wever, Walter ^a   Van Assche, Gert ^a   Rutgeerts, Paul ^a   Vermeire, Severine ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Anti TNF ; Anti tuberculous therapy; De novo tuberculosis; IBD; Immune reconstitution inflammatory syndrome; Screening

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; C REACTIVE PROTEIN; ETHAMBUTOL; INFLIXIMAB; ISONIAZID; MESALAZINE; NORFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANEMIA; ANOREXIA; APPENDICITIS; ARTICLE; BELGIUM; BLOODY DIARRHEA; BRONCHUS BIOPSY; CASE REPORT; CERVICAL LYMPHADENOPATHY; COUGHING; CROHN DISEASE; DISEASE ACTIVITY; DRUG FEVER; ERYTHROCYTE CONCENTRATE; FATIGUE; FEVER; FLU LIKE SYNDROME; GRANULOMATOUS INFLAMMATION; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOTHERAPY; IRON DEFICIENCY; LEUKOCYTOSIS; LUNG INFILTRATE; LYMPHADENOPATHY; MAINTENANCE THERAPY; MALE; MIDDLE AGED; MILIARY TUBERCULOSIS; MYALGIA; MYCOBACTERIUM TUBERCULOSIS; NIGHT SWEAT; PANCOLITIS; PERITONITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECTUM HEMORRHAGE; RELAPSE; REMISSION; SCREENING; SIGMOIDOSCOPY; SKIING; SLEEP DISORDERED BREATHING; SPONDYLOARTHROPATHY; STEROID THERAPY; SWELLING; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULIN TEST; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COLITIS, ULCERATIVE; COMPLICATION; LABORATORY DIAGNOSIS; TUBERCULOSIS, PULMONARY;

ADULT; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; FALSE NEGATIVE REACTIONS; HUMANS; MALE; MIDDLE AGED; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899908177     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.11.008     Document Type: Article

References (19)

1. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
2. WHO report 2011 Global tuberculosis control [2011. http://www.who.int/tb/publications/global_report/en/index.html]. http://www.who.int.
3. Scott Algood H.M., Lin P.L., Flynn J.L. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005, 41:189-193.
4. Gardam M.A., Keystone E.C., Menzies R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet 2003, 3:148-155.
5. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 2005, 44:714-720.
6. Sia I.G., Wieland M.L. Current concepts in the management of tuberculosis. Mayo Clin Proc 2011, 86:348-361.
7. Lee E., Holzman R.S. Evolution and current use of tuberculin test. Clin Infect Dis 2002, 34:365-370.
8. Piana F., Codecasa L.R., Cavallerio P., et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006, 28:31-34.
9. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm.
10. Schoepfer A.M., Flogerzi B., Fallegger S., et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008, 103:2799-2806.
11. Rahier J.F., Ben-Horin S., Chowers Y., et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis Jun 2009, 3(2):47-91.
12. Salmon D. Recommendations about the prevention and management of tuberculosis in patients taking IFX. Joint Bone Spine 2002, 69:170-172.
13. VRGT Diagnose en behandeling van tuberculose: een praktische handleiding voor artsen [2010.http://www.belta.be/images/stories/Aanb_diag_%20behand_TB 2010.pdf]. http://www.vrgt.be.
14. Van Assche G., Lewis J.D., Lichtenstein G.R., et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011, 106:1594-1602.
15. Rivoisy C., Amrouche L., Carcelain G., Séréni D., Bourgarit A. Paradoxical exacerbation of tuberculosis after TNFalpha antagonist discontinuation: beware of immune reconstitution inflammatory syndrome. Joint Bone Spine 2011, 78:312-315.
16. Breen R.A.M., Smith C.J., Bettinson H., et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004, 59:704-707.
17. Garcia Vidal C., Rodriguez Fernandez S., Martinez Lacasa J., et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005, 40:756-759.
18. Melboucy-Belkhir S., Flexor G., Stimemann F., et al. Prolonged paradoxical response to anti-tuberculous treatment after infliximab. J Infect Dis 2010, 14:333-334.
19. Barber D.L., Andrade B.B., Sereti I., Sher A. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev 2012, 10:150-156.